Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
40.86B
Market cap40.86B
Price-Earnings ratio
131.64
Price-Earnings ratio131.64
Dividend yield
Dividend yield
Average volume
1.27M
Average volume1.27M
High today
$311.56
High today$311.56
Low today
$299.69
Low today$299.69
Open price
$303.42
Open price$303.42
Volume
1.50M
Volume1.50M
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

The current Alnylam Pharmaceuticals(ALNY) stock price is $306.30, with a market capitalization of 40.86B. The stock trades at a price-to-earnings (P/E) ratio of 131.64.

On 2026-03-24, Alnylam Pharmaceuticals(ALNY) stock moved within a range of $299.69 to $311.56. With shares now at $306.30, the stock is trading +2.2% above its intraday low and -1.7% below the session's peak.

Trading activity shows a volume of 1.5M, compared to an average daily volume of 1.27M.

Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.

Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.

ALNY News

TipRanks 14h
Alnylam announces set of efforts to improve care for patients with ATTR-CM

Alnylam (ALNY) Pharmaceuticals announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with t...

Simply Wall St 7d
Alnylam’s Cardiovascular RNAi Collaboration With Tenaya Might Change The Case For Investing In ALNY

Earlier this month, Tenaya Therapeutics announced a research collaboration with Alnylam Pharmaceuticals to validate up to 15 gene targets for cardiovascular dis...

Alnylam’s Cardiovascular RNAi Collaboration With Tenaya Might Change The Case For Investing In ALNY

Analyst ratings

71%

of 28 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.